Pages that link to "Q27027963"

The following pages link to mTOR kinase inhibitors as potential cancer therapeutic drugs (Q27027963):

Displaying 50 items.

• Targeting mTOR in Pancreatic Ductal Adenocarcinoma (Q26747291) (← links)
• Role of mTOR Inhibitors in Kidney Disease (Q26747506) (← links)
• Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives (Q28071388) (← links)
• FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance (Q28077347) (← links)
• The multiple cellular functions of the oncoprotein Golgi phosphoprotein 3 (Q28082896) (← links)
• Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth (Q33645556) (← links)
• Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways (Q33709769) (← links)
• The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent (Q33728258) (← links)
• Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells. (Q34466148) (← links)
• Glucose metabolism regulates T cell activation, differentiation, and functions. (Q34999559) (← links)
• mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer (Q35139024) (← links)
• Signaling mechanisms that suppress the cytostatic actions of rapamycin (Q35187701) (← links)
• mTORC2 Deficiency in Myeloid Dendritic Cells Enhances Their Allogeneic Th1 and Th17 Stimulatory Ability after TLR4 Ligation In Vitro and In Vivo. (Q35562874) (← links)
• mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation (Q35685586) (← links)
• VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo (Q35708311) (← links)
• GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth (Q35832276) (← links)
• microRNA-153 Targets mTORC2 Component Rictor to Inhibit Glioma Cells (Q36050424) (← links)
• Glutaminolysis and autophagy in cancer (Q36111779) (← links)
• The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2. (Q36123027) (← links)
• Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle. (Q36187271) (← links)
• Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells (Q36189861) (← links)
• The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent (Q36215450) (← links)
• CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo (Q36320156) (← links)
• Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway (Q36547894) (← links)
• Suppression of the invasive potential of Glioblastoma cells by mTOR inhibitors involves modulation of NFκB and PKC-α signaling (Q36650919) (← links)
• Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation (Q36744735) (← links)
• Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth (Q36916277) (← links)
• Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer (Q37151073) (← links)
• Targeting the LKB1 tumor suppressor (Q37506032) (← links)
• The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models (Q37580269) (← links)
• mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation (Q37604295) (← links)
• Gremlin promotes retinal pigmentation epithelial (RPE) cell proliferation, migration and VEGF production via activating VEGFR2-Akt-mTORC2 signaling. (Q37702395) (← links)
• Targeting mTOR network in colorectal cancer therapy (Q37708005) (← links)
• Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex (Q37721031) (← links)
• Targeting the Mammalian Target of Rapamycin in Lung Cancer. (Q37741531) (← links)
• Regulation of the epithelial Na+ channel by the mTORC2/SGK1 pathway. (Q38545109) (← links)
• Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK. (Q38758962) (← links)
• C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor (Q38792344) (← links)
• The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor (Q38842150) (← links)
• Compound 13, an α1-selective small molecule activator of AMPK, potently inhibits melanoma cell proliferation (Q38843938) (← links)
• CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model. (Q39451659) (← links)
• Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses (Q39546506) (← links)
• Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics (Q41133627) (← links)
• Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma (Q41457277) (← links)
• Preclinical study of CC223 as a potential anti-ovarian cancer agent (Q41709197) (← links)
• Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma (Q41966602) (← links)
• Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma (Q42027870) (← links)
• Cell cycle status dictates effectiveness of rapamycin (Q42090819) (← links)
• High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma (Q46952217) (← links)
• ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo (Q47103348) (← links)